RSS

non-small cell lung cancer (NSCLC)

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved AstraZeneca’s Tagrisso (osimertinib) as a first-line treatment of patients with inoperable or recurrent epidermal growth factor mutation-positive non-small cell lung cancer Read more

News

The Independent Data Monitoring Committee (IDMC) has approved the continuation of the Phase III clinical study into OSE Immunotherapeutics’ treatment for Non-Small Cell Lung Cancer (NSCLC) — Tedopi — after immune checkpoint inhibitor treatment. Read more

News

Following a planned review, the Data Monitoring Committee (DMC) has recommended termination of the Phase Ib/II study of daratumumab in combination with atezolizumab versus atezolizumab monotherapy in patients with previously treated NSCLC Read more

News

AstraZeneca and its global biologics research and development arm, MedImmune, have announced positive overall survival (OS) results of the Phase III PACIFIC trial evaluating Imfinzi (durvalumab) for the treatment of unresectable stage III NSCL Read more

News

A positive opinion has been adopted by the CHMP of the European Medicines Agency, recommending a change to the terms of the marketing authorisation for AstraZeneca’s Tagrisso (osimertinib) to include first-line treatment. Read more

News

The US FDA has expanded its approval of Imfinzi (durvalumab) to now include the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumours are unresectable and have not progressed after chemoradiation treatment. Read more

News

Biopharmaceutical companies, AbbVie and Bristol-Myers Squibb, have announced the formation of a clinical research collaboration to evaluate a combination therapeutic regimen for the treatment of advanced solid tumours. Read more

News

An integrated oncology platform from Crown Bioscience has helped to advance the preclinical development of a HERA-GITRL immunotherapy from Apogenix for non-small cell lung cancer (NSCLC) and head and neck cancer. Read more

Technology